Insider Buying: Neuronetics (NASDAQ:STIM) Major Shareholder Buys $40,860.00 in Stock

Neuronetics, Inc. (NASDAQ:STIM) major shareholder Jorey Chernett bought 18,000 shares of Neuronetics stock in a transaction dated Friday, October 30th. The stock was acquired at an average price of $2.27 per share, with a total value of $40,860.00. Following the acquisition, the insider directly owned 10,620,988 shares of the company’s stock, valued at approximately $24,109,642.76. This represents a 0.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Friday, August 14th, Jorey Chernett purchased 14,000 shares of Neuronetics stock. The shares were acquired at an average price of $3.16 per share, for a total transaction of $44,240.00.

Neuronetics Stock Up 19.5%

NASDAQ:STIM opened at $2.70 on Thursday. The firm has a market capitalization of $205.73 million, a price-to-earnings ratio of -6.14 and a beta of 1.36. Neuronetics, Inc. has a 1-year low of $0.80 and a 1-year high of $3.44. The company has a current ratio of 1.88, a quick ratio of 1.69 and a debt-to-equity ratio of 2.84. The business’s fifty day moving average price is $2.49 and its 200 day moving average price is $1.88.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings data on Wednesday, November 4th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.07. Neuronetics had a negative return on equity of 125.11% and a negative net margin of 19.62%. The firm had revenue of $41.96 million during the quarter, compared to the consensus estimate of $40.42 million. On average, sell-side analysts forecast that Neuronetics, Inc. will post -0.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on STIM. Citigroup reaffirmed a “market outperform” rating on shares of Neuronetics in a research report on Tuesday, July 21st. Wall Street Zen upgraded shares of Neuronetics from a “sell” rating to a “hold” rating in a research report on Sunday, July 12th. BTIG Research reissued a “buy” rating and set a $6.00 target price on shares of Neuronetics in a research note on Thursday, September 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a research note on Monday, September 14th. Finally, B. Riley Financial began coverage on shares of Neuronetics in a research note on Friday, September 11th. They issued a “buy” rating on the stock. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Neuronetics presently has an average rating of “Moderate Buy” and a consensus price target of $4.67.

Key Stories Impacting Neuronetics

Here are the key news stories impacting Neuronetics this week:

• Positive Sentiment: Neuronetics reported Q3 revenue of $41.96 million, up 12.5% year over year and ahead of analyst estimates of about $40.4 million. Its net loss narrowed to $1.7 million, and its loss per share of $0.02 was better than the consensus estimate of a $0.09 loss and the year-ago loss of $0.13 per share. Neuronetics Q3 2026 results
• Positive Sentiment: Major shareholder Jorey Chernett purchased 18,000 shares for about $40,860, adding modestly to an already substantial holding. The buying may be viewed as a confidence signal, though the transaction occurred before the earnings release. Shareholder purchase report
• Neutral Sentiment: The company disclosed inducement awards for 14 non-executive employees. Equity-based awards can support hiring and retention, while potentially diluting shareholders; the announcement does not specify the award details in the provided report. Inducement grant announcement

Hedge Funds Weigh In On Neuronetics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. David J Yvars Group boosted its holdings in shares of Neuronetics by 35.7% during the 2nd quarter. David J Yvars Group now owns 27,550 shares of the company’s stock worth $36,000 after buying an additional 7,250 shares during the period. Fielder Capital Group LLC bought a new position in Neuronetics in the 2nd quarter worth $30,000. State of Wyoming bought a new position in Neuronetics in the 2nd quarter worth $31,000. IMC Chicago LLC acquired a new position in Neuronetics during the 1st quarter worth $40,000. Finally, T3 Companies LLC acquired a new position in Neuronetics during the 3rd quarter worth $88,000. Institutional investors and hedge funds own 53.59% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc is a medical technology company that develops and commercializes noninvasive treatments for psychiatric and neurological disorders. Its primary product is NeuroStar TMS Therapy, which uses transcranial magnetic stimulation to deliver targeted magnetic pulses to areas of the brain associated with mood regulation.

NeuroStar TMS Therapy is cleared by the U.S. Food and Drug Administration for treating major depressive disorder in adults and adolescents, obsessive-compulsive disorder, and depression with anxious distress.